

Saskatchewan Health Authority - Saskatoon Area - ANTIBIOGRAM 2019

LTC Patients - Urinary Isolates

January 1, 2019 - December 31, 2019

NOTE: For non-urinary isolates consult adult inpatient antibiogram

Longterm Care – % Susceptible

# Isolates tested	Penicillin PO/IV	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftazidime	Meropenem	Ertapenem	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Nitrofurantoin (urine only)	Fosfomycin (urine only)	Gentamicin	Tobramycin	Vancomycin
GRAM-NEGATIVE BACTERIA																				
<i>Escherichia coli</i> ¹ -	918	51		78	98	84	91		89	89	100	100	62		72	94	98	89	90	
<i>Enterobacter cloacae</i> ² †-	20	R		R	R	R	R		R	85	100	100	90		95	65	60	100	100	
<i>Klebsiella pneumoniae</i> ¹ -	171	R		88	97	88	94		88	88	100	100	83		83	43	79	90	88	
<i>Klebsiella oxytoca</i> -	30	R		93	97	70	100		97	100	100	100	93		100	87	92	100	100	
<i>Pseudomonas aeruginosa</i> -	54				93					96	96		93					94	100	
<i>Proteus mirabilis</i> -	186	97		100	100	98	99		100	100	100	100	77		97	R	84	96	99	

# Isolates tested	Penicillin PO/IV	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftazidime	Meropenem	Ertapenem	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Nitrofurantoin (urine only)	Fosfomycin (urine only)	Gentamicin	Tobramycin	Vancomycin
GRAM-POSITIVE BACTERIA																				
<i>Staphylococcus aureus</i> , all																				
- methicillin-susceptible (MSSA) -	37		100			100							62		100	95				100
Aerococcus spp.	51	100							94											100
<i>Enterococcus faecalis</i> , urine -	253		100			R	R	R	R	R			77			99				100
<i>Enterococcus faecium</i> urine ³ †-	18	R				R	R	R	R	R			R	R		R				83

R - intrinsically resistant

† Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

¹ Overall extended spectrum beta-lactamase (ESBL) activity was seen in a weighted average of 4.9 % of samples of *E. coli*, *K. pneumoniae* and *P. mirabilis*

² These organisms may produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

³ VRE (vancomycin-resistant Enterococci) isolated from clinical specimens: *E. faecium* 17% (N = 3)